First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)

被引：0
|
作者：
Lorenzi, M. [1 ]
Dal Maso, A. [1 ]
Ferro, A. [1 ]
Polo, V. [2 ]
Scattolin, D. [1 ]
Macerelli, M. [3 ]
Follador, A. [3 ]
Targato, G. [3 ]
Indraccolo, S. [4 ]
Frega, S. [5 ]
Menis, J. [1 ]
Bonanno, L. [5 ]
Guarneri, V. [1 ]
Conte, P. F. [1 ]
Pasello, G. [1 ]
机构：
[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[2] Ca Foncello Hosp, Oncol Unit, AULSS 2 Marca Trevigiana, Treviso, Italy
[3] Azienda Sanit Univ Integrata Udine, Santa Maria Misericordia Hosp, Dept Med Oncol, Udine, Italy
[4] Veneto Inst Oncol IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy
[5] Veneto Inst Oncol IOV IRCCS, Div Med Oncol 2, Padua, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
149P
引用
收藏
页码：S779 / S779
页数：1
相关论文
共 50 条
  • [1] Real-world survival with first-line (1L) chemotherapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)
    Waterhouse, D.
    Betts, K. A.
    Zhao, J.
    Rao, S.
    Gupte-Singh, K.
    Rutstein, M.
    Higashi, M. K.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 29 - U99
  • [2] COSTS OF CARE FOR FIRST-LINE (1L) TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A REAL-WORLD CLAIMS ANALYSIS
    Kish, Jonathan
    Chopra, Dhruv
    Liassou, Djibril
    Lubinga, Solomon
    Hartman, John
    Feinberg, Bruce
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A437 - A438
  • [3] First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study
    Lorenzi, Martina
    Ferro, Alessandra
    Cecere, Fabiana
    Scattolin, Daniela
    Del Conte, Alessandro
    Follador, Alessandro
    Pilotto, Sara
    Polo, Valentina
    Santarpia, Mariacarmela
    Chiari, Rita
    Pavan, Alberto
    Dal Maso, Alessandro
    Da Ros, Valentina
    Targato, Giada
    Vari, Sabrina
    Indraccolo, Stefano
    Calabrese, Fiorella
    Frega, Stefano
    Bonanno, Laura
    Conte, Pier Franco
    Guarneri, Valentina
    Pasello, Giulia
    ONCOLOGIST, 2022, 27 (02): : 87 - E115
  • [4] Real-world (RW) treatment patterns, patient characteristics and outcomes in advanced non-small cell lung cancer (aNSCLC) with PD1/L1 as first-line (1L) therapy in the UK and Germany
    Snee, M.
    Cheeseman, S.
    Levick, B.
    Hall, G.
    Rohde, G.
    Stratmann, J.
    Wolf, A.
    van Gils, C.
    Griner, R.
    Mahmood, A.
    Niklas, N.
    Divan, H. A.
    Krishna, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S52 - S53
  • [5] Global real-world (rw) study of patients (pts) with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with first-line (1L) osimertinib: Interim analysis of an rw pt registry in Germany
    Griesinger, F.
    Popat, S.
    Okhuoya, P.
    Servidio, L.
    Fonseca, M. J.
    Tolani, E.
    Lu, S.
    Zacharias, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1587 - S1587
  • [6] Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C.
    Ho, G.
    Chai, C.
    Alip, A. Bt
    Pang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S998 - S999
  • [7] Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
    Nieva, J.
    Taylor, A.
    Servidio, L.
    Sun, P.
    Okhuoya, P.
    Horvat, P.
    Tolani, E.
    Magee, K.
    Mathur, R.
    Balakrishna, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1113 - S1113
  • [8] Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
    Liam, C. K.
    Chai, C.
    Ho, G.
    Alip, A.
    Wahid, M. I. A.
    Abdullah, M. M.
    Foo, Y. C.
    How, S. H.
    Zaatar, A.
    Lam, K. S.
    Leong, K. W.
    Low, J. S. H.
    Yusof, M. Md
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S848
  • [9] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
    Cam Phuong Pham
    Thi Thai Hoa Nguyen
    Anh Tu Do
    Tuan Khoi Nguyen
    Thi Anh Thu Hoang
    Tuan Anh Le
    Dinh Thy Hao Vuong
    Dac Nhan Tam Nguyen
    Van Khiem Dang
    Thi Oanh Nguyen
    Van Luan Pham
    Minh Hai Nguyen
    Thi Huyen Trang Vo
    Hung Kien Do
    Ha Thanh Vu
    Thi Thuy Hang Nguyen
    Van Thai Pham
    Le Huy Trinh
    Khac Dung Nguyen
    Hoang Gia Nguyen
    Cong Minh Truong
    Tran Minh Chau Pham
    Thi Bich Phuong Nguyen
    BMC Cancer, 24
  • [10] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
    Pham, Cam Phuong
    Nguyen, Thi Thai Hoa
    Do, Anh Tu
    Nguyen, Tuan Khoi
    Hoang, Thi Anh Thu
    Le, Tuan Anh
    Vuong, Dinh Thy Hao
    Nguyen, Dac Nhan Tam
    Dang, Van Khiem
    Nguyen, Thi Oanh
    Pham, Van Luan
    Nguyen, Minh Hai
    Vo, Thi Huyen Trang
    Do, Hung Kien
    Vu, Ha Thanh
    Nguyen, Thi Thuy Hang
    Pham, Van Thai
    Trinh, Le Huy
    Nguyen, Khac Dung
    Nguyen, Hoang Gia
    Truong, Cong Minh
    Pham, Tran Minh Chau
    Nguyen, Thi Bich Phuong
    BMC CANCER, 2024, 24 (01)
12345